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A B S T R A C T
Purpose
To investigate the role of the PER3 circadian rhythm gene, located within the commonly deleted
region of chromosome 1p36, in human breast cancer development.
Patients and Methods
The frequency of genetic alterations at 1p36 and PER3 gene copy number status were analyzed
in 180 lymph node–negative breast cancers from patients who had received treatment with
chemotherapy and/or tamoxifen. The expression levels of PER3 were also analyzed using
published microarray profiles from  400 breast cancer samples. Finally, the effect of loss of Per3
on tumor susceptibility was tested using two mouse models of breast cancer.
Results
Deletion of PER3 is directly related to tumor recurrence in patients with estrogen receptor (ER) –
positive breast cancers treated with tamoxifen. Low expression of PER3 mRNA is associated with
poor prognosis, particularly in a subset of tumors that are ER positive, and either luminal A or
ERBB2-positive tumors. Mice deficient in Per3 showed increased susceptibility to breast cancer
induced by carcinogen treatment or by overexpression of Erbb2.
Conclusion
Disruption of PER3 function may serve as an indicator of probability of tumor recurrence in patients
with ER-positive tumors. Further investigations of this pathway may reveal links between
deregulation of sleep homeostasis and breast tumorigenesis.
J Clin Oncol 28:3770-3778. © 2010 by American Society of Clinical Oncology
INTRODUCTION
Chromosomal region 1p36 is among themost com-
monly deleted regions in human cancers. Deletion
of 1p36 is especially frequent in breast tumors and is
associatedwith progression and lymphnodemetas-
tasis,1 poor prognosis,2 higher rate of recurrence,3
larger tumor size, and DNA aneuploidy.4 However,
nodirect relationship betweenbreast carcinogenesis
orprognosis andanyspecific tumorsuppressorgene
on 1p36 has been established. Recent elegant studies
have identifiedCHD55 andmore recentlyKIF1B6 as
candidate tumor suppressorgenes in this region,but
no specific roles for these genes in breast cancer
development have been demonstrated.
ThehumanPER3gene is locatedwithin1.5Mb
of CHD5, and the mouse homolog is a member
of the period gene family that controls circadian
rhythms.7,8 Members of the period family of circa-
dian rhythmgenes (Per1 andPer2) have been impli-
cated in cell cycle control, DNA damage responses,
and tumorprogression.9-12Although inactivationof
Per3 in themousegermlinehasonly subtle effectson
circadian clock function,13 it has been shown that
Per3 transcripts exhibit a clear circadian rhythm
both in the suprachiasmatic nucleus7 and in mouse
peripheral tissues.14 Similardatahavebeenshown in
humanperipheral bloodcells,where circadianoscil-
lations were more robust for PER3 expression than
for other clock genes includingPER1 and PER2.15,16
The possible functions of PER3 in tumor develop-
ment have not been explored, but links to breast
cancer are supported by biochemical studies dem-
onstrating the existence of complexes, including
proteins of the PER family together with the estro-
gen receptor (ER),17,18 and by reports of association
between a polymorphism in the human PER3 gene
and breast cancer susceptibility.19
The location of the PER3 gene within a region
that is commonlydeleted inbreast cancers suggested
a possible link to epidemiologic studies20,21 showing
an association between disrupted sleep cycles and
higher risk of developing breast cancer. We used a
combination of human breast tumor analysis and
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mouse models to show that disruption of PER3may serve as a prog-
nostic biomarker of tumor recurrence in patients with ER-positive,
luminal A, and/or ERBB2-positive tumors.
PATIENTS AND METHODS
Sample Selection
Weused three previously published breast cancer data sets that included
clinical, gene expression, and/or array comparative genomic hybridization
(CGH) data.22-24 Data on disease-free survival (DFS; defined as the time to a
first event) and overall survival (OS) were available for all patients in the three
data sets except for one patient in samples from a study by Chin et al.24
Copy Number Analysis of PER3
All tumor DNA samples were obtained from frozen breast tumors
with 50% tumor cells.22 The genomic sequence of PER3 (GenBank acces-
sionNM_016831.1) was used to design a set of primers and probes specific to
the PER3 gene (Primer Express software version 1.0; Applied Biosystems,
Foster City, CA; see Data Supplement for detailed description).
PER3 Gene Expression Analysis
We examined PER3 expression in 413 breast tumor expression arrays
taken fromstudiesbyvandeVijver et al23 (n295)andChinet al24 (n118).
In each data set, a sample si in the set S was labeled as “PER3 low,” “PER3
normal,” or “PER3 high” using the rule:
If si (mean [S] 1⁄2 standard deviation [S]), assign LOW.
If si (mean [S] 1⁄2 standard deviation [S]), assign HIGH.
Otherwise, assign NORMAL.
This method allowed us to compare relative PER3 expression levels
across both data sets fused as a single group of patients.
Statistical Analysis
The association betweenPER3 deletion orPER3 expression and clinical-
pathologic parameters was analyzed using Fisher’s exact test. All reported P
valueswere two-tailed. Significant differences inDFS andOS timewere calcu-
lated using the Cox proportional hazard (log-rank) test. Multivariate Cox
regression analysis was used to prove statistical independence of PER3 from
other known prognostic factors. Statistical analysis was performed using SPSS
version 12.0 (SPSS, Chicago, IL).
Mice and Tumor Induction
Wild-type (Per3/) and Per3 knockout (Per3/) 129/sv mice (pro-
vided by Drs. Y.H. Fu and L.J. Pta´cˇek, University of California, San Francisco
[USCF], San Francisco, CA) were bred and treated according to Laboratory
Animal Resource Center regulations. Female mice 7 weeks old from the F2
intercross population (Per3/, Per3/, and Per3/) were treated with six
doses of 1mgof 7,12-dimethylbenz[a]anthracene (DMBA)diluted in corn oil
byweeklyoral gavage.A secondgroupofmicewas treatedwith cornoil only as
a groupcontrol. In a secondexperiment,malePer3/micewere crossedwith
femaleFVBmiceexpressing theNeu (ErbB2)proto-oncogeneundercontrolof
themousemammary tumor virus (MMTV) 3 long terminal repeats promot-
er25 (providedbyDr.Z.Werb,UCSF) togenerateF1 transgenicmiceheterozy-
gous for Per3 (Neu/Per3/). F1 males and females were intercrossed to
produce the F2 generation consisting ofNeu/Per3
/,Neu/Per3/, andNeu/
Per3/ animals. Identification of animal genotypes is described in the
Data Supplement.
In the DMBA gavage experiment, female mice were examined every 3
days for sickness or symptoms of tumor development for up to 19.7 months.
MMTV neu/Per3 transgenic female mice were examined weekly by palpation
for mammary tumor development for up to 25.8 months. Mice that showed
significant weight loss, morbidity, or excessive tumor burden were killed by
cervical dislocation after being anesthetized according to the UCSF Animal
Care andUse protocol. Tumors and tissues were fixed in 4%neutral buffered
paraformaldehyde forhistologicexamination.Mice founddeadwerecensored
from the study.
RESULTS
Deletion of 1p36 and Loss of PER3 Genetic Variants in
Breast Cancers
Wepreviously reported genome-wide array CGHprofiles of 185
lymph node–negative breast cancers from a Spanish cohort,22 of
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Fig 1. Association between PER3 dele-
tion and disease-free survival in breast
cancer patients. (A) TaqMan copy number
analysis of PER3 in all patients, (B) in
patients who received no treatment or (C)
were treated with anthracycline chemo-
therapy, and (D) in a subset of 59 patients
who were estrogen receptor–positive
and/or progesterone receptor–positive and
were treated only with tamoxifen.
PER3 Disruption in ER-Positive Breast Cancer
www.jco.org © 2010 by American Society of Clinical Oncology 3771
whom 85 received anthracycline chemotherapy (chemo group) and
95 received no chemotherapy (non-chemo group). To search for
genetic events related to resistance to hormonal (tamoxifen) therapy,
we divided the non-chemo group into two subgroups on the basis
of whether they had received hormonal treatment. Of the 95 pa-
tients in the non-chemo group, 59 patients with ER-positive and/or
progesterone-positive tumors received tamoxifen, whereas 36 did not
receive any treatment. Analysis of CGH profiles for these patients
revealed that deletion of chromosome 1p was associated with recur-
rence in the subgroup of ER-positive tamoxifen-treated patients
(P .05 after multiple testing correction using method of Benjamini
and Hoffberg; Fig DS1).26
The chromosome 1p36 locus is frequently deleted in many hu-
man tumors, but the region of deletion is large. Separate, nonoverlap-
ping chromosome fragments have been implicated,27-29 suggesting
that multiple tumor suppressor genes are involved. We considered
PER3 to be a good candidate for involvement in breast cancer because
of its locationwithinoneof theminimal deletion regionson1p36.2,5,6
aswell as the epidemiologic19 andmechanistic17 data linkingcircadian
rhythm genes to hormone status and breast cancer. We therefore
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Fig 2. Association between PER3 gene
expression and survival of breast cancer
patients. (A) PER3 low expression (red) ver-
sus PER3 normal/high expression (blue) in
all patients. (B) Comparison of PER3 expres-
sion with estrogen receptor (ER) status. DFS,
disease-free survival; SE, standard error.
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examined the copy number status of PER3 by quantitative TaqMan
analysis (AppliedBiosystems) inDNAsamples from180breast cancer
patients. The relationship between the frequency of deletion or copy
number gain and clinico-pathologic characteristics of the patients is
shown in Table DS1. The number of copies of PER3 showed a signif-
icant gene dosage associationwith recurrence-free survival at 10 years
(P  .01; Fig 1A). The proportion of disease-free surviving patients
after 10 years was lowest in patients with single-copy PER3 deletion
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Fig 3. Effect of PER3 expression levels on survival according to molecular subtypes. Kaplan-Meier estimates of disease-free survival (DFS) among the 413 patients,
according to the PER3 expression. (A) Basal versus non-basal tumors; (B) luminal A versus luminal B and ERBB2-positive subgroups of tumors. SE, standard error.
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(56% 8.6; red line) compared with those having two (75% 4.0;
blue line) ormore (89% 5.6; gray line) copies of thePER3 gene (Fig
1A). Further analysis showed that the effect ofPER3deletionwasmost
pronounced in the tamoxifen-treated group, with no significant asso-
ciation in the nontreated or chemotherapy-treated groups (Figs 1B
through 1D). Among the 59 patients who received only tamoxifen
treatment (Fig 1D), patients with single-copy PER3 deletions had a
significantly lower DFS rate at 10 years (47% 12) than those with
normalPER3 (84%6)orcopynumbergains (100%DFS;P .007).
Follow-up for all patients was 82 months (range, 1.5 to 219months).
To look forpotential inactivatingmutations inPER3 inbreast cancers,
we initially sequenced the complete coding region of PER3 in a panel
of 35 breast cancer cell lines. No clear pathogenic (nonsense or mis-
sense) mutation was identified. However, many known30 and some
unknown polymorphisms and alternative splicing isoforms were
found (see Data Supplement for full detailed description). One of the
polymorphic variants identified by sequencing had been associated
with breast cancer susceptibility in other studies19 and also with dis-
ruption of sleep homeostasis.31-33
Low Expression of PER3 Is Associated With
Reduced Survival
We next examined PER3 gene expression in 413 breast tumor
expression arrays taken from two publicly available data sets (van de
Vijver et al23 [n 295] andChin et al24 [n 118]). A full description
of the stratification of the patients into different subgroups according
to PER3 expression together with DFS curves for all patients in each
subgroup is shown in Figures 2 and 3. Patients with lower PER3
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Fig 4. Kaplan-Meier estimates of overall survival (OS). The different expression levels of PER3 were evaluated in all the patients (A) and the different subgroups of
patients based on (B) ER-positive, (C) ER-negative, (D) basal, (E) nonbasal, (F) ERBB2-positive, (G) luminal A, and (H) luminal B tumors. SE, standard error.
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expression (“PER3 low” [n 122]) were significantly more likely to
recur than those with normal or higher expression (“PER3 normal/
high”[n291];P .013;Fig2A).DFSanalysis showedthatPER3 low
patients had significantly worse survival rates thanPER3 normal/high
patients (P .001). ER status is an important predictor of recurrence
and greatly influences treatment regimens.34,35 If low expression of
PER3 segregates with ER status, any effect of low PER3 expression
could be confounded with the effect of ER status. We therefore per-
formed a subset analysis of PER3 in ER-positive and ER-negative
tumors. LowPER3 levelswere significantly associatedwith recurrence
(P  .01) and shorter DFS times (P  .001) in patients with ER-
positive, but not ER-negative tumors (Fig 2B). We conclude that the
association between low PER3 expression and recurrence in the com-
plete patient sample setwas drivenby theER-positive tumors,withno
effect being detected in the ER-negative tumors. These data are in
agreement with the independent association between deletion of
PER3 and recurrence specifically in the tamoxifen-treated (ER-
positive tumors) patients in Figure 1D.
We next asked whether stratifying tumors according to their
molecular subtype36,37 could reveal additional information. The tu-
mors were labeled using a nearest centroid classifier, and a label was
assigned only if correlation with a target class was above 0.1.31,32 This
resulted in samples labeled luminal A (n 90), luminal B (n 68),
ERBB2 (n 56), normal-like (n 17), basal (n 73), or unclassified
(n 109; Fig 3 and Fig DS4). Of these groups, low PER3 expression
had significant association with recurrence only in luminal A–type
(P  .007) or ERBB2-type tumors (P  .03; Fig 3B). None of the
patients with ERBB2-positive tumors received anti–ERBB2-targeted
therapy. DFS analysis for luminal A–type and ERBB2-type tumors
indicated that PER3 low patients had lower DFS rates at 10 years than
patients with PER3 normal/high (luminal A: 28%  10 v 84%  4;
P .001 and ERBB2: 30% 8 v 68% 8; P .004). There was also
a striking effect on OS rate at 10 years in all the patients and in the
subgroups of ER-positive, luminalA, andERBB2patients (Fig 4): The
10-year OS rate for patients with ER-positive tumors and with low
PER3 was 55%  6 versus 79%  3 for normal/high patients
(P .001; Fig 4B). TheOS rate was 25% 8 for patients with ERBB2
and low PER3 versus 70% 7 for patients with ERBB2 and normal/
high PER3 (P  .001; Fig 4F). The OS rate at 10 years in luminal A
patients with low PER3 was 34%  11 versus 83%  3 for patients
with normal/highPER3 (P .001; Fig 4G). Importantly,multivariate
analysis showed that PER3 expression is independently significant
from all the prognostic factors tested both for DFS (P .001) and
OS (P .001; Table 1).
The possible links between expression levels and probability of
tumor recurrence were evaluated for all 54 annotated genes in the
1p36.31 to 1p36.22 region (chromosome 1: 6,084,440 to 9,512,808
[3.5Mb]).Gene expressionwasdiscretized as described forPER3, and
log-rank P values were calculated using the survival library for R. This
analysis showed that PER3 was the only gene with an uncorrected
P .05 in all data sets analyzed. Although chromosome engineering
studies have previously identified CHD5 as a candidate tumor sup-
pressor gene within theminimal deletion region on 1p36.25, no asso-
ciation of CHD5 expression levels with recurrence or survival was
found in any of the subgroups of breast cancer patients analyzed (Figs
DS5 and DS6). These data do not exclude the possibility that CHD5
plays an important role as a tumor suppressor in other tumor types.
Inactivation of Per3 Increases Breast Tumor
Susceptibility in Mouse Models
To investigate a possible causal association between loss of Per3
function and breast tumor development, we performed two stud-
ies involving mouse models of breast cancer (Fig 5 and Table 2). A
total of 86mice carrying normal or inactivated alleles of the Per3 gene
Table 1. Cox Proportional Hazard Ratio Multivariate Analysis
Variable
Disease-Free Survival Overall Survival
Hazard Ratio 95% CI P Hazard Ratio 95% CI P
All patients
PER3 2.13 1.40 to 3.24  .001 2.04 1.34 to 3.10 .001
Tumor size 1.72 1.13 to 2.63 .012 2.02 1.31 to 3.12 .002
Age  40 years 0.49 0.32 to 0.74 .001 0.54 0.35 to 0.83 .005
ER 0.75 0.49 to 1.15 .19 0.53 0.35 to 0.80 .003
Lymph node 1.36 0.90 to 2.06 .14 1.85 1.18 to 2.77 .007
Tumor grade
Good 0.93 0.55 to 1.60 .8 1.05 0.61 to 1.80 .87
Intermediate 1.18 0.74 to 1.89 .48 1.38 0.87 to 2.20 .17
ER-positive patients
PER3 2.92 1.71 to 4.97  .001 2.63 1.49 to 4.63 .001
Tumor size 1.62 0.96 to 2.63 .072 1.87 1.05 to 3.32 .03
Age  40 years 0.58 0.33 to 0.99 .047 0.57 0.32 to 1.04 .06
ER
Lymph node 1.40 0.83 to 2.39 .21 2.07 1.18 to 2.77 .02
Tumor grade
Good 1.14 0.59 to 2.23 .69 1.09 0.54 to 2.24 .8
Intermediate 1.34 0.73 to 2.46 .34 1.32 0.70 to 2.49 .38
NOTE. Risk of distant recurrence or death among patients with breast cancer.
Abbreviation: ER, estrogen receptor.
All tumors are ER positive.
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(17 wild-type [Per3/], 35 heterozygous [Per3/], and 34 null
[Per3/])were treatedbyoral gavagewithDMBA, aprotocol known
to induce breast cancer in sensitive strains of mice.38 Eight mice (two
heterozygous and six null) were found dead before the end point, and
no tissues were collected from them. The median follow-up of the
remaining 78mice included in the studywas 8.3months (range, 3.8 to
15.0months).Allof themice treatedwithDMBAdeveloped tumorsof
various kinds, including lymphoma and solid tumors of the lung,
ovary, and skin (TableDS5).However, development of breast tumors
was specifically associated with Per3 deficiency. Thirty-six percent of
Per3/ mice treated with DMBA developed breast tumors, while
12% of the Per3/ mice developed breast tumors. In striking con-
trast, none of the control Per3/ mice developed a breast tumor
(P .005; Fig 3A).Agroupof 65mice (19wild-type, 25heterozygous,
and 21 null) were used as controls with no DMBA gavage treatment.
Two of the Per3/ control mice developed sporadic breast tumors,
but none of the remaining mice were found sick or developed any
other class of tumor during the time course of this experiment
(24months).
The secondmousemodel was based on the observation that low
levels of PER3 expression were strongly associated with recurrence in
ERBB2-type human breast cancers. MMTV-Neu mice overexpress
ErbB2 in the mammary gland and spontaneously develop breast tu-
mors.26 We generated a total of 79 MMTV-Neu–positive mice, of
which 30 (38%)were Per3/, 35 (44%)were Per3/, and 14 (18%)
were Per3/. The median follow-up of all mice was 14.9 months
(range, 6.3 to 25.8 months). All Per3/ mice developed breast tu-
mors, whereas 25 (71%) of the Per3/ and 14 (47%) of the Per3/
mice developed breast tumors. The proportion of Per3/ null mice
free of tumors at 15 months (21% 8) was significantly lower than
the proportion in the heterozygous and the wild-typemice (63% 6
inbothPer3/ andPer3/;P .003).Histologic analysis of tumors
from both models of breast cancer showed that loss of Per3 did not
affect the tumor class ormorphology, since bothDMBA-induced and
MMTV-Neu–induced tumors in Per3/mice resembled equivalent
tumors from Per3wild-type animals (data not shown). We also eval-
uated the possible loss of the wild-type Per3 allele in tumors from the
Per3 heterozygous mice. No loss was observed, suggesting that ho-
mozygous loss is not essential in this mouse model.
DISCUSSION
Ourdata indicate thatdeletionand/or reducedexpressionof thePER3
gene on human chromosome 1p36 is associated with breast cancer
recurrence, particularly in patients with ER-positive tumors treated
with tamoxifen who did not receive chemotherapy. No effect of dele-
tion was seen in patients with basal type ER-negative breast tumors.
Within the ER-positive category, the effect was primarily in tumors
classified as luminal A–type or ERBB2-type, but not in the luminal
B–type, which shares some expression featureswith basal tumors.36,37
Direct evidence for a causal role for loss of PER3, rather than an
alternative gene in this commonly deleted region of the genome,5,6
comes from analysis of two different mouse models of breast cancer.
Bothchemically inducedandNeu(ErbB2)–inducedbreast cancersare
increased in frequency and/or reduced in latency in mice carrying
inactivated Per3 alleles. Although these data do not prove that Per3 is
the only functional tumor suppressor gene in this chromosome inter-
val, they indicate that Per3 is a bona fide tumor suppressor in these
mouse models, with a key role in breast tissue.
While disruptionof themouse period gene familymembersPer1
andPer2bygene targeting inducesbiologic clockphenotypes,39 loss of
Per3 function induces only subtle effects on circadian rhythm.13,40
Nevertheless, evidence in favor of PER3 involvement in both sleep
disruption and breast cancer comes from studies of a human struc-
tural polymorphism in the PER3 coding sequence that has been asso-
ciated with delayed sleep phase syndrome, diurnal preference, and
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Fig 5. Effect of loss of Per3 on tumor susceptibility in two different mouse
models. (A) Breast cancer incidence in a group of mice treated with
7,12-dimethylbenz[a]anthracene on the basis of the different genotypes (wild
type/[WT], heterozygous/[Het], and null /). (B) Kaplan-Meier estimates
of probability of tumor-free survival in the group of mouse mammary tumor
virus neu-Per3 mice.
Table 2. Tumor-Free Rate for MMTV-Neu–Positive Mice
No. of
Mice
Median
Follow–Up
(months)
Range
(months)
Tumor-Free Rate at
15 Months  SE (%)
30 16 7.5-26.4 63  6
35 16 6.3-26.5 63  6
14 13 9.8-22.5 21  8
Abbreviations: MMTV, mouse mammary tumor virus; SE, standard error.
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waking performance,31,41,42 but also with increased breast cancer
risk,19 particularly in premenopausal women.
Although the specificmolecularmechanisms remain to be eluci-
dated, increasing evidence points to a role for circadian rhythm genes
in cell cycle control and DNA damage responses11,43 as well as in
hormonal control of gene expression.17,18 PER2 has been identified as
an estrogen-inducible ER corepressor that forms heterodimers with
PER3 to enter the nucleus. Deletion of PER3 prevents nuclear import
and, instead, promotes accumulation of PER2 in the cytoplasm.44
Whether coordinated functional deregulation of all period family
genes occurs in breast cancers remains to be determined.
There are several clinical implicationsof theseobservations. First,
the presence of PER3 deletions in ER-positive tumors may identify
patients who do not respond to tamoxifen-based hormone therapy
and who may benefit from other therapeutic regimens. Second, pre-
viousdata fromclinical trials of chronotherapy suggest that the timing
of cancer treatment during the day may affect individual patient re-
sponses.45,46 Elucidation of the relationship between control of sleep
homeostasis and circadian rhythms, PER gene expression, and DNA
damage responsesmay help in understanding the epidemiologic data
linking sleep disruption to breast cancer susceptibility,17,20,21 but fur-
ther detailed studies will be required to elucidate the exact mecha-
nisms involved. Finally, small-molecule drugs that help to restore the
balance of the biologic clock in individualswith frequent sleepdisrup-
tion may have potential as chemopreventive agents for breast and
some other cancer types.
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